Physician profile
Michael E Mayle
NPI 1851403307
$2,202.14
in general payments reported to CMS, 2019-2025
21 companies · $88.27 in 2025
The $88.27 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $299 · 2021: $509 · 2022: $422 · 2023: $228 · 2024: $456 · 2025: $88.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $771.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $953.50 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $399.24 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals Lp | $178.69 | 2021-2024 | Farxiga |
| Lilly USA, LLC | $87.55 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $83.74 | 2021 | |
| Janssen Pharmaceuticals, INC | $78.08 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.31 | 2019-2020 | |
| Abbvie INC. | $54.79 | 2023 | |
| Novartis Pharmaceuticals Corporation | $53.90 | 2019-2023 | |
| Glaxosmithkline, LLC. | $45.27 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $28.98 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.25 | 2019 | |
| Merck Sharp & Dohme LLC | $24.38 | 2023 | Vaxneuvance, Gardasil 9, Proquad |
| Astellas Pharma US INC | $22.06 | 2023 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.72 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $18.40 | 2019 | |
| Exact Sciences Corporation | $17.55 | 2025 | The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $13.70 | 2019 | |
| Amarin Pharma, INC. | $12.29 | 2020 | |
| Allergan, INC. | $11.89 | 2020 | |
| Pfizer INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mayle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.